Phase 1
The death of Sen. John McCain helped raise awareness about the plight of brain tumor patients and the lack of movement on developing new therapies for this disease over the past several years. But now, Houston-based Moleculin Biotech has launched a clinical trial that could be a game-changer if all goes well.
IPH5401 is a first-in-class antibody targeting the C5a receptor expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment
6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with unremarkable safety profile; No DLTs or related SAEs
Imugene Limited today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.
BioChaperone® Pramlintide Insulin (BC Pram Ins) is the first product to clinically demonstrate the feasibility of a fixed-ratio co-formulation of pramlintide and human insulin
Forendo Commences Phase Ia Study for FOR-6219 for Endometriosis
Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups
Part 1 top-line data of the NOX-A12 trial to be presented at the September ‘Fourth International Cancer Immunotherapy Conference’
SpringWorks Therapeutics and BeiGene, Ltd. have teamed up to develop therapeutics that will target advanced solid tumors that contain RAS mutations, as well as other MAPK aberrations.
Shares of Synlogic, Inc. are climbing this morning after the New York Times highlighted the company’s proprietary synthetic biotics being used to treat patients with PKU. The company also released positive interim data from an ongoing study of its PKU treatment.
PRESS RELEASES